Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma

NCT00316940 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.

NCT NCT00316940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00316940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Oncotherapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2005
Completion date
February 28, 2011
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm